Phase II studies in advanced, recurrent pelvic malignancies: conducted by the Gynecologic Oncology Group, Experimental Design and Experience.
D000230:Adenocarcinoma / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002945:Cisplatin / Q000627:therapeutic use; D003961:Dianhydrogalactitol / Q000627:therapeutic use; D004341:Drug Evaluation; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008453:Maytansine / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local; D010386:Pelvic Neoplasms / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use; D011929:Razoxane / Q000627:therapeutic use; D012107:Research Design; D014227:Triazines / Q000627:therapeutic use
D000970:Antineoplastic Agents; D010879:Piperazines; D014227:Triazines; D008453:Maytansine; D003961:Dianhydrogalactitol; D011929:Razoxane; C003905:3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione; D005047:Etoposide; C012071:triazinate; D002945:Cisplatin